Record Identifier,Sub# ,Age at Treatment,Gender,Race,Ethnicity,Diagnosis,Histology,Stage (at time of treatment),"Treatment Line (not including adjuvant), 1*= treatment naïve", Treatment,Mechanism,Start,Sample collection date,De-identified ID,Responder,Comments
2,150003,46,Female,White,non-Hispanic,NSCLC- Squamous ,Lung,3,2,Nivolumab,PD1 inhibitor,7/17/15,7/17/15,MCCT-24.2,Yes,
3,150005,63.6,Female,White,non-Hispanic,NSCLC- Squamous ,Lung,4,2,Nivolumab,PD1 inhibitor,7/28/15,7/28/15,MCCT-24.3,No,
5,150006,58,Female,White,non-Hispanic,NSCLC- Adeno ,Lung,4,6,Nivolumab,PD1 inhibitor,8/19/15,8/19/15,MCCT-24.5,No,
4,150007,79,Male,White,non-Hispanic,NSCLC- Adeno ,Lung,4,5,Nivolumab + Avastin,PD1 inhibitor + VEGF Inhibitor,8/19/15,8/18/15,MCCT-24.4,Yes,
8,150011,75,Male,white,non-Hispanic,NSCLC- Adeno ,Lung,4,2,Nivolumab,PD1 inhibitor,10/5/15,10/5/15,MCCT-24.8,No,
10,150013,70.8,Female,White,non-Hispanic,NSCLC- Adeno ,Lung,4,7,Nivolumab,PD1 inhibitor,10/26/15,10/26/15,MCCT-24.10,No,
11,150022,82.8,Male,White,non-Hispanic,NSCLC- Squamous ,Lung,4,2,Nivolumab,PD1 inhibitor,12/18/15,12/16/15,MCCT-24.12,Indeterminate,
12,150031,58.7,Female,White,non-Hispanic,NSCLC- Adeno ,Lung,4,3,Nivolumab,PD1 inhibitor,2/9/16,2/9/16,MCCT-24.14,No,
7,150032,87,Male,White,non-Hispanic,NSCLC- Adeno ,Lung,4,5,Nivolumab,PD1 inhibitor,2/10/16,9/15/15,MCCT-24.7,Indeterminate,
13,150080,64,Female,Black or African American,non-Hispanic,NSCLC- Large cell ,Lung,4,2,Nivolumab,PD1 inhibitor,8/2/16,8/2/16,MCCT-24.17,Yes,
14,150083,77,Female,White,non-Hispanic,NSCLC- Adeno ,Lung,4,4,151524: Part A Avelumab + PF-05082566,4-1BB/CD137 Agonist  + PDL1 Inhibitor,8/22/16,8/22/16,MCCT-24.18,No,
16,150088,68.7,Male,White,non-Hispanic,NSCLC- Adeno ,Lung,4,4,Pembrolizumab,PD1 inhibitor,9/1/16,9/1/16,MCCT-24.20,No,
17,150093,55,Female,White,non-Hispanic,Melanoma of RU chest wall,Melanoma,4,2,Ipilimumab,CTLA-4 inhibitor,9/14/16,9/14/16,MCCT-24.21,Yes,
20,150094,64,Female,Other Race or Mixed Race,Hispanic,NSCLC- Adeno ,Lung,4,2,Nivolumab,PD1 inhibitor,10/13/16,10/13/16,MCCT-24.24,No,
19,150095,27.6,Male,White,Non-Hispanic,"Melanoma, unknown primary",Melanoma,4,2,Pembrolizumab + Dabrafenib + Trametanib,PD1 inhibitor + BRAF inhibitor + MEK inhibitor,4/28/17,10/1/16,MCCT-24.23,No,
9,150104,64,Female,Other Race or Mixed Race,Hispanic,NSCLC- Squamous ,Lung,4,2,151512: FivePrime FPA008 + Nivolumab,CSF1R inhibitor + PD1 inhibitor,11/7/16,10/14/15,MCCT-24.9,Indeterminate,Pt opted to come off study due to side effects
21,150108,63,Female,Black,non-Hispanic,NSCLC,Lung,4,2,151512: FivePrime FPA008 + Nivolumab,CSF1R inhibitor + PD1 inhibitor,12/28/16,12/9/16,MCCT-24.26,Yes,
22,150109,62,Male,White,Hispanic,Melanoma,Melanoma,3,2,Nivolumab + Ipilimumab,PD1 inhibitor + CTLA-4 inhibitor,12/14/16,12/14/16,MCCT-24.27,Indeterminate,Stopped treatment due to adverse events
23,150113,80,Female,White,non-Hispanic,NSCLC,Lung,4,2,Nivolumab,PD1 inhibitor,1/12/17,1/12/17,MCCT-24.28,Indeterminate,
6,150117,60,Male,White,non-Hispanic,Melanoma,Melanoma,4,7,160819: CAVATAK (Coxsackievirus A21) + Ipilimuab,ICAM-1 target + CTLA-4 Inhibitor,2/1/17,8/22/16,MCCT-24.6,No,
24,150126,41,Male,White,non-Hispanic,Melanoma,Melanoma,3b,1*,160962: Ipilimumab +/- placebo ,CTLA-4 inhibitor ,3/17/17,3/17/17,MCCT-24.29,Yes,
18,150141,71,Female,White,non-Hispanic,Melanoma,Unknown primary,4,1,Ipilimumab + Nivolumab,CTLA-4 inhibitor + PD1 inhibitor,6/8/17,6/8/17,MCCT-24.22,Yes,
25,150143,58,Male,White,non-Hispanic,Melanoma,Melanoma,4,1*,160819: CAVATAK (Coxsackievirus A21) + Ipilimuab,ICAM-1 target + CTLA-4 Inhibitor,4/13/17,6/28/17,MCCT-24.30,No,
26,150146,53,Male,White,non-Hispanic,Melanoma,Melanoma,4,7,161386: Triplet- Nivolumab + Ipilimumab + BMS-986205 IDO,PD1 inhibitor + CTLA-4 inhibitor + IDO1,8/7/17,8/7/17,MCCT-24.31,No,
27,150156,84,Male,white,non-Hispanic,NSCLC- Adeno ,Lung,4,1*,Pembrolizumab,PD1 inhibitor,8/28/17,8/28/17,MCCT-24.32,Yes,
28,150161,62,Female,White,non-Hispanic,NSCLC- Adeno ,Lung,4,2,161386: Triplet- Nivolumab + Ipilimumab + BMS-986205 IDO,PD1 inhibitor + CTLA-4 inhibitor + IDO1,10/9/17,10/9/17,MCCT-24.33,No,
29,150162,78,Male,White,non-Hispanic,NSCLC- Adeno ,Lung,4,2,161386: Triplet- Nivolumab + Ipilimumab + BMS-986205 IDO,PD1 inhibitor + CTLA-4 inhibitor + IDO1,10/16/17,10/16/17,MCCT-24.34,No,
30,150163,60,Male,Other Race or Mixed Race,Hispanic,Melanoma,Melanoma,3b,1*,Nivolumab,PD1 inhibitor,10/18/17,10/18/17,MCCT-24.35,No,
31,150166,70,Male,White,non-Hispanic,Melanoma,Melanoma,2c,0,Pembrolizumab,PD1 inhibitor,11/29/17,11/29/17,MCCT-24.36,Indeterminate,
32,150171,56,Female,White,non-Hispanic,NSCLC- Adeno ,Lung,4,3,151172: MEDI9447 + Durvalumab,anti-CD73 + PD1 inhibitor,1/8/18,1/8/18,MCCT-24.37,No,
33,150178,74,Female,White,non-Hispanic,NSCLC- Sarcomatoid,Lung,4,2,161386: Triplet- Nivolumab + Ipilimumab + BMS-986205 IDO,PD1 inhibitor + CTLA-4 inhibitor + IDO1,2/20/18,2/20/18,MCCT-24.38,Yes,
34,150182,60,Male,White,non-Hispanic,Melanoma,Melanoma,4,2,170929: NKTR-214 + Nivolumab,IL2 + PD1 inhibitor,2/22/18,2/20/18,MCCT-24.39,Yes,
35,150186,74,Male,White,non-Hispanic,Melanoma,Melanoma,4,1,Nivolumab + Ipilimumab,PD1 inhibitor + CTLA-4 inhibitor,3/7/18,3/7/18,MCCT-24.40,Yes,
15,150199,68,Male,White,non-Hispanic,NSCLC- Squamous ,Lung,4,4,Nivolumab + Ipilimumab,PD1 inhibitor + CTL4,5/23/18,5/23/18,MCCT-24.19,No,
36,150209,77,Female,White,non-Hispanic,NSCLC- Adeno ,Lung,4,3,151172: MEDI9447 + Durvalumab,anti-CD73 + PD1 inhibitor,7/23/18,7/23/18,MCCT-24.41,No,
37,150215,67,Female,white,non-Hispanic,NSCLC- Adeno ,Lung,4,2,Pembrolizumab,PD1 inhibitor,8/13/18,8/13/18,MCCT-24.42,No,
39,150224,52,Male,White,non-Hispanic,Melanoma,Melanoma,4,1*,Nivolumab + Ipilimumab,PD1 inhibitor + CTLA-4 inhibitor,9/14/18,9/14/18,MCCT-24.44,Yes,
40,150229,68.5,Female,White,non-Hispanic,NSCLC,Lung,4,2,151172: MEDI9447 + Durvalumab,anti-CD73 + PD1 inhibitor,9/11/18,10/2/18,MCCT-24.45,Indeterminate,Did not end up starting immunotherapy but treated with darbrafenib + trametinib + osimertinib
1,150230,47,Male,White,non-Hispanic,Melanoma,Melanoma,4,5,Nivolumab + Bevacizumab,PD1 inhibitor,10/5/18,10/5/18,MCCT-24.1,Yes,Nivolumab adjuvant intent for brain
38,150238,64,Male,White,non-Hispanic,Melanoma + NSCLC-adenosquamous ,Melanoma + Lung,4,2,170929: NKTR-214 + Nivolumab,IL2 + PD1 inhibitor,12/4/18,12/4/18,MCCT-24.43,Yes,
41,150242,81,Male,White,non-Hispanic,Melanoma,Melanoma,4,3,160819: CAVATAK (Coxsackievirus A21) + Ipilimuab,ICAM-1 target + CTLA-4 Inhibitor,1/7/19,1/7/19,MCCT-24.46,Yes,